(RTTNews) - Ono Pharmaceutical Co. announced that Ono Pharma Taiwan Co., a Taiwanese subsidiary of Ono, received the additional approval of Opdivo Intravenous Infusion, an anti-PD-1 antibody, on January 14 from the Taiwan Food and Drug Administration in Taiwan, in combination with ipilimumab, for the treatment of adult patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. The approval is based on the results from the CheckMate-8HW study.
Opdivo as a single agent, or in combination with Yervoy, was previously granted accelerated approval in MSI-High/dMMR CRC adult patients that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan. The company noted that the TFDA decision converts this second-line indication to full approval for Opdivo monotherapy, and expands the indication for Opdivo plus Yervoy into the first-line setting based on the CheckMate-8HW study.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
